Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01387958
Recruitment Status : Terminated (Terminated early due to futility)
First Posted : July 6, 2011
Last Update Posted : May 8, 2012
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This is a proof of concept study, designed to look at the safety and antiviral activity of LCQ908 in hepatitis C infected patients.

Condition or disease Intervention/treatment Phase
Hepatitis C Drug: LCQ908 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Double-blind, Randomized, Placebo-controlled, Multi-center Trial, to Determine the Safety and Antiviral Effect of 14 Days of LCQ908 Monotherapy in Hepatitis C Infected Patients
Study Start Date : July 2011
Actual Primary Completion Date : February 2012
Actual Study Completion Date : February 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: LCQ908 Drug: LCQ908
Placebo Comparator: Placebo Drug: Placebo

Primary Outcome Measures :
  1. Measure: Change in hepatitis C viral load as assessed by PCR [ Time Frame: 2 weeks ]

Secondary Outcome Measures :
  1. Measure: Safety assessments will include vital signs, electrocardiograms (ECG), liver function tests, and adverse events. [ Time Frame: 28 days ]
  2. Measure: LCQ908 concentrations in the blood [ Time Frame: over 21 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent.
  • Male and female subjects 18 to 65 years of age with hepatitis C infections (genotypes 1, 2 or 3).
  • No prior therapy or inadequate response to therapy for hepatitis C.
  • Weight at least 50 kg and body mass index (BMI) within 18 - 35 kg/m2.

Exclusion Criteria:

  • Use of other investigational drugs within at least 30 days of enrollment
  • Women of child-bearing potential.

Other protocol-defined inclusion/exclusion criteria apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01387958

Layout table for location information
New Zealand
Novartis Investigative Site
Auckland, New Zealand
Novartis Investigative Site
Christchurch, New Zealand
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals Identifier: NCT01387958    
Other Study ID Numbers: CLCQ908A2214
First Posted: July 6, 2011    Key Record Dates
Last Update Posted: May 8, 2012
Last Verified: May 2012
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Hepatitis C virus
Chronically infected
treatment naive
non responders to prior therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Antiviral Agents
Anti-Infective Agents